FR22C1044I2 - ANTAGONISTS OF THE CGRP RECEIVER - Google Patents

ANTAGONISTS OF THE CGRP RECEIVER

Info

Publication number: FR22C1044I2
Authority: FR; France
Prior art keywords: antagonists; cgrp; receiver; cgrp receiver
Prior art date: 2009-10-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR22C1044C

Other languages

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-10-14

Filing date

2022-08-11

Publication date

2023-11-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43242489&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR22C1044(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2022-08-11 Application filed filed Critical

2022-09-30 Publication of FR22C1044I1 publication Critical patent/FR22C1044I1/en

2023-11-17 Application granted granted Critical

2023-11-17 Publication of FR22C1044I2 publication Critical patent/FR22C1044I2/en

Status Active legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

FR22C1044C 2009-10-14 2022-08-11 ANTAGONISTS OF THE CGRP RECEIVER Active FR22C1044I2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US25147709P	2009-10-14	2009-10-14
PCT/US2010/052433 WO2011046997A1 (en)	2009-10-14	2010-10-13	Cgrp receptor antagonists

Publications (2)

Publication Number	Publication Date
FR22C1044I1 FR22C1044I1 (en)	2022-09-30
FR22C1044I2 true FR22C1044I2 (en)	2023-11-17

Family

ID=43242489

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR22C1044C Active FR22C1044I2 (en)	2009-10-14	2022-08-11	ANTAGONISTS OF THE CGRP RECEIVER

Country Status (35)

Country	Link
US (2)	US8314117B2 (en)
EP (1)	EP2488512B1 (en)
JP (3)	JP5836279B2 (en)
KR (3)	KR101875353B1 (en)
CN (1)	CN102656159B (en)
AR (2)	AR078638A1 (en)
AU (1)	AU2010306954B2 (en)
BR (1)	BR112012008828B1 (en)
CA (2)	CA2968176C (en)
CL (1)	CL2012000925A1 (en)
CO (1)	CO6460732A2 (en)
CY (1)	CY2022023I2 (en)
DK (1)	DK2488512T3 (en)
EA (1)	EA020409B1 (en)
ES (1)	ES2441192T3 (en)
FR (1)	FR22C1044I2 (en)
HR (1)	HRP20140111T1 (en)
HU (1)	HUS2200033I1 (en)
IL (1)	IL219120A (en)
LT (1)	LTPA2022516I1 (en)
LU (1)	LUC00272I2 (en)
MX (1)	MX2012004182A (en)
NL (1)	NL301187I2 (en)
NO (1)	NO2022033I1 (en)
NZ (1)	NZ599281A (en)
PE (1)	PE20121137A1 (en)
PL (1)	PL2488512T3 (en)
PT (1)	PT2488512E (en)
RS (1)	RS53149B (en)
SI (1)	SI2488512T1 (en)
SM (1)	SMT201400019B (en)
TN (1)	TN2012000139A1 (en)
TW (1)	TWI465448B (en)
WO (1)	WO2011046997A1 (en)
ZA (1)	ZA201203452B (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8314117B2 (en) *	2009-10-14	2012-11-20	Bristol-Myers Squibb Company	CGRP receptor antagonists
US8669368B2 (en) *	2010-10-12	2014-03-11	Bristol-Myers Squibb Company	Process for the preparation of cycloheptapyridine CGRP receptor antagonists
US8748429B2 (en) *	2011-04-12	2014-06-10	Bristol-Myers Squibb Company	CGRP receptor antagonists
CN104136437B (en) *	2012-02-27	2016-05-11	百时美施贵宝公司	N-(5S, 6S, 9R)-4-(2-oxo-2,3-dihydro-1H-imidazo [4,5-B] pyridine-1-yl) piperidines-1-carboxylic acid 5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydrochysene-5H-cycloheptatriene is [B] pyridine-9-base ester Hemisulphate also
US9227973B2 (en) *	2012-05-09	2016-01-05	Merck Sharp & Dohme Corp.	Pyridine CGRP receptor antagonists
EP2815749A1 (en)	2013-06-20	2014-12-24	IP Gesellschaft für Management mbH	Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
TW201718574A (en) *	2015-08-12	2017-06-01	美國禮來大藥廠	CGRP receptor antagonists
GB201519195D0 (en)	2015-10-30	2015-12-16	Heptares Therapeutics Ltd	CGRP Receptor Antagonists
GB201519196D0 (en)	2015-10-30	2015-12-16	Heptares Therapeutics Ltd	CGRP Receptor Antagonists
GB201519194D0 (en)	2015-10-30	2015-12-16	Heptares Therapeutics Ltd	CGRP receptor antagonists
GB201707938D0 (en)	2017-05-17	2017-06-28	Univ Sheffield	Compounds
JP2021519288A (en)	2018-03-25	2021-08-10	バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッドＢｉｏｈａｖｅｎＰｈａｒｍａｃｅｕｔｉｃａｌＨｏｌｄｉｎｇＣｏｍｐａｎｙＬｔｄ．	Limegepant for CGRP-related disorders
CN114805206B (en) *	2021-01-27	2025-01-14	奥锐特药业(天津)有限公司	Industrial preparation method of high optical purity remegipam intermediate
EP4301362A1 (en)	2021-03-02	2024-01-10	CGRP Diagnostics GmbH	Treatment and/or reduction of occurrence of migraine
WO2023026205A1 (en)	2021-08-24	2023-03-02	Cgrp Diagnostics Gmbh	Preventative treatment of migraine
CN115850266A (en) *	2021-09-26	2023-03-28	奥锐特药业(天津)有限公司	Novel crystal form of rimazepam and preparation method thereof
CN116554164A (en) *	2022-01-27	2023-08-08	奥锐特药业(天津)有限公司	Preparation method of zimetapam
WO2023175632A1 (en) *	2022-03-17	2023-09-21	Msn Laboratories Private Limited, R&D Center	Solid state forms of (5s,6s,9r)-5-amino-6-(2,3difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1-yl)-1-piperidinecarboxylate hemisulfate and processes for preparation thereof
CN116478211B (en) *	2022-04-19	2023-10-24	石家庄迪斯凯威医药科技有限公司	Novel CGRP receptor antagonist and application thereof
CN115060824B (en) *	2022-06-14	2024-03-12	浙江宏元药业股份有限公司	Liquid chromatography detection method for enantiomer impurities of ramiazepam intermediate
WO2024022434A1 (en) *	2022-07-29	2024-02-01	熙源安健医药（上海）有限公司	Pyridocycloheptane derivative, preparation method therefor, and use thereof
CN115677694A (en) *	2022-11-30	2023-02-03	南通常佑药业科技有限公司	Synthetic method of rimazepam
WO2024180562A1 (en) *	2023-03-02	2024-09-06	Natco Pharma Limited	A process for the preparation of pure crystalline rimegepant and its salts thereof
CN116768938A (en) *	2023-05-17	2023-09-19	南京艾德凯腾生物医药有限责任公司	Preparation method of iron catalyst and remijipan intermediate
CN119661518A (en) *	2023-09-21	2025-03-21	成都康弘药业集团股份有限公司	A small molecule drug for the treatment of CGRP-related disorders
CN117486798B (en) *	2023-12-21	2025-02-07	南京威凯尔生物医药科技有限公司	A crystal form of remegipam intermediate hydrochloride and preparation method thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JO2355B1 (en)	2003-04-15	2006-12-12	ميرك شارب اند دوم كوربوريشن	CGRP receptor antagonists
EP1726590A4 (en)	2004-03-05	2009-07-15	Banyu Pharma Co Ltd	D RIV CYCLOALKANOPYRIDINE
MX2007004393A (en)	2004-10-13	2007-04-25	Merck & Co Inc	Cgrp receptor antagonists.
US20060084708A1 (en)	2004-10-14	2006-04-20	Bayer Materialscience Llc	Rigid foams with good insulation properties and a process for the production of such foams
ATE503755T1 (en)	2004-10-22	2011-04-15	Merck Sharp & Dohme	CGRP RECEPTOR ANTAGONISTS
JP2009533438A (en)	2006-04-10	2009-09-17	メルクエンドカムパニーインコーポレーテッド	Method for producing pyridine heterocyclic CGRP antagonist intermediate
US8143403B2 (en)	2008-04-11	2012-03-27	Bristol-Myers Squibb Company	CGRP receptor antagonists
US8044043B2 (en) *	2008-04-11	2011-10-25	Bristol-Myers Squibb Company	CGRP receptor antagonists
US8314117B2 (en) *	2009-10-14	2012-11-20	Bristol-Myers Squibb Company	CGRP receptor antagonists

2010
- 2010-10-12 US US12/902,714 patent/US8314117B2/en active Active
- 2010-10-13 EA EA201270561A patent/EA020409B1/en not_active IP Right Cessation
- 2010-10-13 HR HRP20140111AT patent/HRP20140111T1/en unknown
- 2010-10-13 CA CA2968176A patent/CA2968176C/en active Active
- 2010-10-13 AU AU2010306954A patent/AU2010306954B2/en active Active
- 2010-10-13 KR KR1020177018206A patent/KR101875353B1/en active Active
- 2010-10-13 MX MX2012004182A patent/MX2012004182A/en active IP Right Grant
- 2010-10-13 EP EP10768347.6A patent/EP2488512B1/en active Active
- 2010-10-13 SI SI201030486T patent/SI2488512T1/en unknown
- 2010-10-13 RS RS20140035A patent/RS53149B/en unknown
- 2010-10-13 ES ES10768347.6T patent/ES2441192T3/en active Active
- 2010-10-13 KR KR1020187018446A patent/KR101990755B1/en active Active
- 2010-10-13 NZ NZ599281A patent/NZ599281A/en unknown
- 2010-10-13 PL PL10768347T patent/PL2488512T3/en unknown
- 2010-10-13 WO PCT/US2010/052433 patent/WO2011046997A1/en active Application Filing
- 2010-10-13 JP JP2012534309A patent/JP5836279B2/en active Active
- 2010-10-13 CA CA2777518A patent/CA2777518C/en active Active
- 2010-10-13 KR KR1020127012197A patent/KR101755742B1/en active Active
- 2010-10-13 BR BR112012008828-9A patent/BR112012008828B1/en active IP Right Grant
- 2010-10-13 PE PE2012000490A patent/PE20121137A1/en active IP Right Grant
- 2010-10-13 PT PT107683476T patent/PT2488512E/en unknown
- 2010-10-13 DK DK10768347.6T patent/DK2488512T3/en active
- 2010-10-13 CN CN201080056672.4A patent/CN102656159B/en active Active
- 2010-10-14 TW TW099135091A patent/TWI465448B/en active
- 2010-10-14 AR ARP100103755A patent/AR078638A1/en not_active Application Discontinuation
2012
- 2012-03-28 TN TNP2012000139A patent/TN2012000139A1/en unknown
- 2012-04-05 IL IL219120A patent/IL219120A/en active IP Right Grant
- 2012-04-12 CL CL2012000925A patent/CL2012000925A1/en unknown
- 2012-04-26 CO CO12068979A patent/CO6460732A2/en unknown
- 2012-05-11 ZA ZA2012/03452A patent/ZA201203452B/en unknown
- 2012-10-16 US US13/652,690 patent/US20130053570A1/en not_active Abandoned
2014
- 2014-02-17 SM SM201400019T patent/SMT201400019B/en unknown
2015
- 2015-04-30 JP JP2015092727A patent/JP6109874B2/en active Active
2017
- 2017-03-08 JP JP2017043761A patent/JP6258537B2/en active Active
- 2017-11-13 AR ARP170103159A patent/AR110069A2/en not_active Application Discontinuation
2022
- 2022-07-12 CY CY2022023C patent/CY2022023I2/en unknown
- 2022-07-14 NL NL301187C patent/NL301187I2/en unknown
- 2022-07-18 HU HUS2200033C patent/HUS2200033I1/en unknown
- 2022-07-19 LU LU00272C patent/LUC00272I2/fr unknown
- 2022-07-22 NO NO2022033C patent/NO2022033I1/en unknown
- 2022-08-02 LT LTPA2022516C patent/LTPA2022516I1/lt unknown
- 2022-08-11 FR FR22C1044C patent/FR22C1044I2/en active Active

Also Published As

Publication number	Publication date
US8314117B2 (en)	2012-11-20
CL2012000925A1 (en)	2012-08-31
CA2968176C (en)	2019-11-26
AR078638A1 (en)	2011-11-23
EA020409B1 (en)	2014-10-30
BR112012008828B1 (en)	2021-11-23
EA201270561A1 (en)	2012-12-28
JP2013508281A (en)	2013-03-07
TWI465448B (en)	2014-12-21
CO6460732A2 (en)	2012-06-15
PL2488512T3 (en)	2014-04-30
KR20180080343A (en)	2018-07-11
JP5836279B2 (en)	2015-12-24
FR22C1044I1 (en)	2022-09-30
US20130053570A1 (en)	2013-02-28
KR20170081737A (en)	2017-07-12
NL301187I2 (en)	2022-08-04
KR20120087940A (en)	2012-08-07
ZA201203452B (en)	2014-10-29
AR110069A2 (en)	2019-02-20
AU2010306954A1 (en)	2012-05-03
IL219120A0 (en)	2012-06-28
PT2488512E (en)	2014-02-24
TW201118096A (en)	2011-06-01
CA2777518A1 (en)	2011-04-21
JP6258537B2 (en)	2018-01-10
KR101875353B1 (en)	2018-07-05
JP2017125054A (en)	2017-07-20
CY2022023I1 (en)	2023-01-05
HK1169390A1 (en)	2013-01-25
IL219120A (en)	2016-12-29
KR101990755B1 (en)	2019-06-18
LTPA2022516I1 (en)	2022-08-25
SMT201400019B (en)	2014-05-07
SI2488512T1 (en)	2014-02-28
HUS2200033I1 (en)	2022-08-28
ES2441192T3 (en)	2014-02-03
KR101755742B1 (en)	2017-07-07
CA2777518C (en)	2017-07-04
LUC00272I2 (en)	2025-05-12
TN2012000139A1 (en)	2013-09-19
CN102656159A (en)	2012-09-05
EP2488512A1 (en)	2012-08-22
PE20121137A1 (en)	2012-08-30
DK2488512T3 (en)	2014-02-24
BR112012008828A2 (en)	2020-09-15
AU2010306954B2 (en)	2016-05-26
JP6109874B2 (en)	2017-04-05
HRP20140111T1 (en)	2014-03-14
JP2015163625A (en)	2015-09-10
CY2022023I2 (en)	2023-01-05
MX2012004182A (en)	2012-05-29
NZ599281A (en)	2013-01-25
CN102656159B (en)	2015-07-01
RS53149B (en)	2014-06-30
EP2488512B1 (en)	2013-11-27
CA2968176A1 (en)	2011-04-21
NO2022033I1 (en)	2022-07-22
US20110251223A1 (en)	2011-10-13
WO2011046997A1 (en)	2011-04-21

Publication	Publication Date	Title
FR22C1044I2 (en)	2023-11-17	ANTAGONISTS OF THE CGRP RECEIVER
CY2023022I1 (en)	2024-02-16	PIPERIDINONE AZAINDANE CARBOXAMIDE CGRP RECEPTOR ANTAGONISTS
LTC2579894I2 (en)	2020-03-25	CGRP antibodies
SMT201600078B (en)	2016-04-29	ANTAGONIST OF THE CGRP RECEPTOR
EP2585064A4 (en)	2014-01-15	ANTAGONISTS OF C5AR
EP2480576A4 (en)	2013-04-10	ANTAGONISTS OF PCSK9
ECSP12012034A (en)	2012-08-31	PCSK9 ANTAGONISTS
PT2513093E (en)	2014-10-22	NEW CCR2 RECEIVER ANTAGONISTS AND THEIR USES
IL239604A0 (en)	2015-08-31	Antagonists against vegf and their uses
EP2911675A4 (en)	2016-06-01	ANTAGONISTS OF THE 2-PYRIDYLOXY-3-SUBSTITUTED-4-NITRILE OREXIN RECEPTOR
PT2593452T (en)	2017-04-24	HETEROCYCLICAL COMPOUNDS OF THE IP RECEIVER
DK2443104T3 (en)	2013-05-06	DISUBSTITUTED PHTHALAZINE-HEDGEHOG-STI ANTAGONISTS
EP2721016A4 (en)	2014-10-08	ANTAGONISTS OF TRPV4
EP2637656A4 (en)	2014-04-23	PIPERIDINONE CARBOXAMIDE INDANES, CGRP RECEPTOR ANTAGONISTS
EP2254413A4 (en)	2011-10-26	CGRP RECEPTOR ANTAGONISTS OF THE IMIDAZOBENZAZEPINE TYPE
EP2654423A4 (en)	2014-05-28	AZAINDANE ANTAGONISTS HETEROCYCLIC CARBOXAMIDES MERGED FROM CGRP RECEPTORS
BRPI0817835A2 (en)	2015-03-31	CGRP ANTAGONISTS
EP2685826A4 (en)	2014-09-03	PIPERIDINONE CARBOXAMIDE SPIROHYDANTOIN, CGRP RECEPTOR ANTAGONISTS
EP2654421A4 (en)	2014-06-18	CONDENSED HETEROCYCLIC INDANECARBOXAMIDE CGRP RECEPTOR ANTAGONISTS
EP2627329A4 (en)	2014-03-05	TRPA1 RECEIVER ANTAGONIST
EP2458991A4 (en)	2012-12-12	RADIOACTIVELY MARKED CGRP ANTAGONISTS
EP2539706A4 (en)	2013-07-31	ARYLPIPERAZONE ANTAGONISTS OF OPIOID RECEPTORS
EP2341919A4 (en)	2012-05-30	CGRP RECEPTOR ANTAGONISTS
EP2340025A4 (en)	2012-05-09	CGRP RECEPTOR ANTAGONISTS
EP2488186A4 (en)	2013-07-17	ANINEOPLASTIC USES OF ARTERINE ANTAGONISTS